A multifaceted cancer immunotherapy based on an immune checkpoint-modulating chimeric oncolytic virus vector in combination with a dendritic cell vaccine

Project Information

ONCO-VAX

Grant agreement ID: 853433

DOI

10.3030/853433

Project closed

EC signature date 18 March 2020

Start date 1 April 2020

End date 31 March 2026

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost

€ 1 499 988,00

EU contribution

€ 1 499 988,00

Coordinated by

KLINIKUM DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (TUM KLINIKUM)
Germany

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (6)

Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy

Author(s): Alberto Reale, Arianna Calistri, Jennifer Altomonte
Published in: Pharmaceutics, Issue 13, 2025, Page(s) 2192, ISSN 1999-4923
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics13122192

Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies

Author(s): Dirk M. Nettelbeck, Mathias F. Leber, Jennifer Altomonte, Assia Angelova, Julia Beil, Susanne Berchtold, Maike Delic, Jürgen Eberle, Anja Ehrhardt, Christine E. Engeland, Henry Fechner, Karsten Geletneky, Katrin Goepfert, Per Sonne Holm, Stefan Kochanek, Florian Kreppel, Lea Krutzke, Florian Kühnel, Karl Sebastian Lang, Antonio Marchini, Markus Moehler, Michael D. Mühlebach, Ulrike Naumann, Rom
Published in: Viruses, Issue 13/8, 2021, Page(s) 1420, ISSN 1999-4915
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/v13081420

Syncytial death mediated by oncolytic rVSV-NDV dynamically activates immunogenic apoptosis and necroptosis in human lung cancer cells

Author(s): Fabian Kortum, Nina Hartmann, Alexander Bryan, Sonja Glauß, Jennifer Altomonte
Published in: Molecular Therapy Oncology, Issue 33, 2025, Page(s) 201027, ISSN 2950-3299
Publisher: Elsevier BV
DOI: 10.1016/j.omton.2025.201027

Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma

Author(s): Teresa Krabbe, Janina Marek, Tanja Groll, Katja Steiger, Roland M. Schmid, Angela M. Krackhardt, Jennifer Altomonte
Published in: Cancers, Issue 13/5, 2021, Page(s) 1044, ISSN 2072-6694
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers13051044

Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy

Author(s): Janina Marek, Lorenz Hanesch, Teresa Krabbe, Nadia El Khawanky, Simon Heidegger, Jennifer Altomonte
Published in: Molecular Therapy - Oncolytics, Issue 30, 2025, Page(s) 117-131, ISSN 2372-7705
Publisher: Elsevier BV
DOI: 10.1016/j.omto.2023.08.001

A Novel Chimeric Oncolytic Virus Mediates a Multifaceted Cellular Immune Response in a Syngeneic B16 Melanoma Model

Author(s): Sonja Glauß, Victoria Neumeyer, Lorenz Hanesch, Janina Marek, Nina Hartmann, Gabriela M. Wiedemann, Jennifer Altomonte
Published in: Cancers, Issue 16, 2025, Page(s) 3405, ISSN 2072-6694
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers16193405

Intellectual Property Rights

Patent (1)

AN IMMUNE CHECKPOINT-MODULATING VSV-NDV HYBRID VIRUS FOR ONCOLYTIC VIRUS IMMONOTHERAPY OF CANCER

Application/Publication number: 20 205209
Date: 2020-11-02
Applicant(s): KLINIKUM DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (TUM KLINIKUM)